Startups
A best in class, patented, platform technology for the local and targeted delivery of highly potent therapeutic proteins to the CNS and beyond. Release Therapeutics - Treating genetic disorders without gene therapies.
Overview
Founded date
2005
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 22, 2026 | Release Therapeutics Secures Innosuisse Funding to Expand Encapsulated Cell Technology for Sanfilippo Syndrome Type IIIA | The competitive funding reflects confidence in the translational potential of the Company’s platform, supporting its expansion into a second rare CNS indication Our ECT platform is designed to enable sustained delivery of therapeutic protei... |
| Sep 24, 2025 | Business and clinical advancements propel Swiss biotech companies | Topadur is currently conducting a Phase 2a clinical trial evaluating TOP-N53 in patients with systemic sclerosis-related digital ulcers, a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic di... |
| Sep 4, 2025 | Release Therapeutics Grants Exclusive License for MVX-ONCO to Geneva University Hospital and University of Geneva | Release Tx logo The agreement unlocks new potential for the clinical development of the legacy oncology platform, as Release Therapeutics advances its focus on CNS therapies. This licensing agreement advances our platform in parallel across... |
| Feb 12, 2025 | Startups strengthen teams for accelerated growth | Release Therapeutics (RTx) is a Geneva-based company on a mission to treat genetic diseases of the central nervous system (CNS) without gene therapy. It is developing a breakthrough, implantable cell encapsulation platform technology to ov... |
| Feb 7, 2025 | The Rise of Innovation: Spotlight on Swiss Startups in 2025 | In the heart of Switzerland, innovation is blossoming. The ZKB Pionierpreis Technopark 2025 has set the stage for a remarkable showcase of talent. With a record 54 applications, the competition is fierce. This year, a surge of 25% in submis... |
| Feb 5, 2025 | IMD Startup competition announces 27th edition winners | The annual IMD Startup Competition aims to support promising early-stage companies by offering them valuable insights and assistance from experienced managers, notably from IMD’s EMBA and MBA participants. This year’s edition features 22 c... |
| Jan 30, 2025 | Release Therapeutics Announces New CEO to Advance Groundbreaking Treatment for Brain Disorders | Julien Grogg, PhD, MBA — CEO of Release Therapeutics Release Tx logo Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study To the families who have shared their children's MLD journe... |
| Aug 13, 2024 | Brewing a New Future: Arda Biomaterials’ Journey from Waste to Luxury | In the heart of London, where the echoes of history meet the pulse of innovation, a new kind of craftsmanship is brewing. Arda Biomaterials, a startup founded in 2022, is transforming spent grain from the craft beer industry into luxurious,... |
| Aug 7, 2024 | Release Therapeutics secures CHF 3.3 million in seed funding | Metachromatic Leukodystrophy (MLD) is a rare genetic disorder of the nervous system stemming from a deficiency in the lysosomal enzyme, arylsulfatase A (ARSA); it is most common in toddlers aged 12 to 20 months (late infantile MLD). Tragic... |
Show more
Reviews 0
FAQ about Release Tx
When was Release Tx founded?
Release Tx was founded in 2005.
What has the press written about Release Tx?
Parsers VC has collected 13 articles mentioning Release Tx, among them “Release Therapeutics Secures Innosuisse Funding to Expand Encapsulated Cell Technology for Sanfilippo Syndrome Type IIIA” (Oct 22, 2026) and “Business and clinical advancements propel Swiss biotech companies” (Sep 24, 2025).
Is Release Tx still active?
Yes, Release Tx is active; its latest activity on Parsers VC dates from Oct 23, 2026.